reason report
management expect hep author gener increas gross profit
margin per rx
bottom line today news gilead mp launch
author gener ag two hep drug put signific
pressur dplo op accord dplo manag
gross profit per rx gross profit margin per rx
author gener increas rel origin brand
dplo abl negoti better buy-sid margin
author gener even though multipl manufactur
manag also inform us hep less total dplo
revenu news today interest exampl
manufactur essenti creat new author gener
product new list price seem account larg portion
rebat flow origin higher-cost brand
product way reduc out-of-pocket cost member
co-pay deduct tie list price also indic
market roughli much money may flow
broader suppli chain channel gener show market
gilead seem will creat new product may price
near net price dplo manag indic us
chang materi earn gross profit gross profit
margin ag higher origin brand express
script esrx mp seem fine chang pbm
offer either old product high rebat plan sponsor
newer lower-cost author gener lower price assum
price without chang rebat system monday morn
author gener epclusa harvoni hep drug januari
compani claim move could save medicar part
beneficiari out-of-pocket cost step toward
reduc list price one compani press report disclos
past year averag discount list price
encourag move reduc list price show
market price reduc within current market structur
without chang rebat system
dplo reduc hep exposur dramat tradit
dplo heavili expos hep present headwind
throughout much howev believ dplo reduc
exposur hep substanti estim hep
revenu estim drop revenu
year-end link accord compani dplo current
hep exposur continu work dplo
exposur chang assum dplo pbm retent rate
higher overal market may earn
exposur pbm due chang howev manag
inform us gross profit per rx gross margin per rx like
increas ag specialti book busi gilead set
pleas refer page import disclosur price chart analyst certif
new trend influx new could benefit dplo
expect chang materi impact dplo earn
link gilead press releas link link
link esrx respons link
david larsen cfa certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
diplomat share trade ev/ebitda includ increment debt np
ldi deal higher group averag believ premium deserv given dplo growth
profil potenti dplo acquir larger enterpris good posit rapidli grow specialti
market improv sentiment next month expect dplo trade
ev/ebitda estim given stabil dir fee challeng hepat environ abil
dplo win new busi pbm well potenti takeout rate stock outperform
risk valuat
competit high specialti pharmaci industri highli competit current domin three player
esrx mp op mp given rapid specialti market growth spur new drug approv
drug price inflat expect specialti market remain attract new entrant market particip
diplomat also sever retail partnership pbm relationship custom develop acquir
specialti pharmaci may result custom loss diplomat
reimburs pressur could impact growth profit specialti drug spend scrutin
payor includ govern payor medicar medicaid legisl bodi pressur mount limit
reimburs runaway cost specialti drug could put downward pressur price trend could
advers impact diplomat growth requir diplomat deliv addit valu ad servic payor
limit distribut agreement drug access emerg limit distribut model specialti drug
manufactur repres opportun diplomat also risk compani longer abl secur limit
distribut agreement lose access drug specif manufactur diplomat current reli celg op
signific portion drug diplomat revenu came specialti drug
 integr rapid expans diplomat incorpor tuck-in acquisit complement organ
growth risk associ integr custom technolog servic distribut
diplomat excess facil capac posit compani absorb volum increas success growth
also reli hire new employe given high-touch servic compon associ specialti pharmaci
well retain key employe manag member
litig risk diplomat handl sensit patient inform reli inform technolog system
could becom compromis secur breach could result lawsuit exposur compani also
provid limit compound servic could expos compani certain litig risk
esrx share current trade adjust ep estim
histor averag next month expect share trade deal price
price target ep view high expect cigna
transact close use slightli higher averag multipl pt given pend ci transact
encourag specialti growth comment around re-invest back platform believ
servic level improv although believ esrx price aggress retain custom
believ esrx better posit head given servic improv see opportun
win increment share although stagnat mail penetr rate slowdown gener launch repres
threat key pillar esrx busi model view given run-up share price deal
still highli competit market rate esrx share market perform
risk valuat
complianc extens healthcar law regul place govern pbm behavior state
feder level mani law regul pertain fraud abus privaci consum protect plan
design restrict drug price medicar medicaid reimburs drug import insur regul
signific custom concentr esrx depend relationship retail pharmaci dispens
prescript member compani lose materi amount contract abil dispens
medic member could impair potenti result loss busi given esrx
largest pbm term adjust prescript think unlik retail chain would termin
contract compani loss contract creat signific earn headwind
pbm market competit pbm industri highli competit account come renew
put bid variou competitor includ like bid aggress offer servic appear
modestli differ esrx contract typic last three year retent rate usual
high level competit allow client demand price reduct and/or larger share rebat
healthcar reform pbm risk legal process surround healthcar reform
believ transpar languag materi impact pbm could prove risk busi
client may seek higher share rebat wholesal may tri negoti favor term
ci/esrx transact doj regul block ci/esrx transact could signific downsid
risk stock
price target inc base averag four approach believ
reason basi valu stock today approach trough price earn multipl larg cap
slow-growth medic product busi long term revenu multipl larg cap medic product stock
slow growth outlook sum part valuat exist franchis discount cash flow dcf use
trough consensu forward earn multipl slow-growth medic product stock sni gsk
celg appli ep estim gilead give price altern
appli ex-growth large-cap medic product celg revenu multipl revenu
estim deriv impli valu impli one year price target use sum part
valuat exist franchis get price consist primarili price compani hiv
franchis hcv product lastli dcf use forecast free cash flow
appli growth rate termin cash flow forecast discount valu back present
wacc give present valu averag four approach price target
risk valuat
risk view outlook valuat gilead includ major chang label price reimburs
coverag compani exist hiv hcv product emerg aggress price discount rebat
valu eros hiv hcv categori current forecast failur
compani princip pipelin asset selonsertib nash filgotinib ra ibd advanc develop
commerci opportun better perform valu expect includ delay limit
develop profil adopt competit hiv product success develop underappreci
element compani portfolio fxr agonist inhibitor follow-on car-
indic stronger-than-expect convers current hiv patient gilead next gener taf-bas
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark
market capit less billion
capit billion
health index issuer
health index issuer market
inform includ limit price quot statist obtain sourc
believ reliabl repres accur complet reli
upon inform subject chang without notic provid inform purpos
regard offer sell solicit offer buy product
inform relat firm offic director employe proprietari account affili may
posit long short secur refer report and/or relat secur
time time may increas decreas posit express view contrari contain
report firm salespeopl trader profession may provid oral written market
commentari trade strategi contrari opinion express report firm proprietari
account may make invest decis inconsist opinion express report
past perform secur guarante predict futur perform transact strategi
describ herein may suitabl investor addit inform avail upon request
contact editori depart one feder street floor boston
like firm employe analyst receiv compens impact among factor overal firm
profit includ revenu among busi unit institut equiti invest
bank analyst howev compens specif invest bank servic transact
contribut firm invest bank activ
medacorp network healthcar profession attorney physician key opinion leader
specialist access leerink provid inform use analyst prepar research
statement valuat risk cover compani client refer http //
send request leerink partner llc editori
leerink partner llc make market diplomat pharmaci inc express script hold compani
leerink initi coverag dplo outperform rate novemb
leerink place outperform rate esrx oct
leerink place outperform rate juli
member finra/sipc leerink partner llc right reserv document may reproduc
circul without written author
director equiti research
associ director research
director research geoffrey porg mbb
mid- small-cap biotechnolog
avenu america fl
